Table 2

Baseline demographic characteristics according to follow-up groups
Groups Age ± SD* Gender Education Living
Female ≤ 7 yerars Couple Comorbidity Drug use
n (%) n (%) n (%) ± SD* ± SD*
Municipality
Stimulation 81.6 ± 6.7 59(57) 88(85) 48(46) 1.82 ± 1.7 4.89 ± 3.3
Standard care 4.89 ± 3.3 54(65) 65(79) 37(45) 1.65 ± 1.1 5.40 ± 3.9
p-value 0.12 0.25 0.34 0.83 0.45 0.34
Drug
Donepezil 80.80 ± 6.8 62(67) 82(89) 39(42) 1.90 ± 1.7 5.10 ± 3.3
Placebo 80.85 ± 7.3 50(54) 70(75) 46(49) 1.59 ± 1.2 5.16 ± 3.8
p-value 0.96 0.07 0.014 0.30 0.15 0.90
Combination
Donepezil + stimulation 81.32 ± 7.0 31(60) 47(90) 28(54) 2.02 ± 2.0 4.92 ± 2.8
Placebo + Standard care 79.81 ± 8.1 22(54) 29(71) 19(46) 1.51 ± 1.1 5.41 ± 3.9
p-value 0.34 0.57 0.015 0.47 0.14 0.48
Head to head
Stimulation therapy 81.89 ± 8.3 27(53) 40(78) 24(47) 1.61 ± 1.4 4.88 ± 3.7
Donepezil 80.17 ± 6.4 28(74) 32(86) 15(39) 1.76 ± 1.3 5.26 ± 4.0
p-value 0.21 0.046 0.33 0.45 0.61 0.65

*Mean values ± standard deviation.

Andersen et al.

Andersen et al. BMC Neurology 2012 12:59   doi:10.1186/1471-2377-12-59

Open Data